Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635) – Q1 FY27 Results (Quarter ended 30 June 2026)

Introduction

Piramal Pharma Limited (PPL) filed a press release and investor presentation on 29 July 2026 with the BSE and NSE, announcing its unaudited standalone and consolidated financial results for the first quarter of FY 2027 (Q1 FY27).

---

Consolidated Financial Highlights

Particulars	Q1 FY27 (₹ Cr)	Q1 FY26 (₹ Cr)	% Change
Revenue from Operations	2,270	1,934	+17 %
– CDMO	1,187	997	+19 %
– CHG (Complex Hospital Generics)	743	637	+17 %
– PCH (Consumer Healthcare)	347	302	+15 %
EBITDA	285	165	+72 %
EBITDA Margin	12.5 %	8.5 %	–
PAT (before exceptional item)	(69)	(102)	+32 %
Exceptional Item	–	21	–
PAT (after exceptional item)	(69)	(82)	+15 %

Note: The exceptional item in Q1 FY26 reflects a one‑time insolvency proceeds received from a claim against a third‑party supplier (NCLT, Nov 2023).

Additional Income & Expenses (₹ Cr)

• Other Income: 89 (↑ 53 %)
• Material Cost: 852 (↑ 23 %)
• Employee Expenses: 676 (↑ 9 %)
• Other Expenses: 547 (↑ 6 %)
• Interest Expenses: 88 (↑ 2 %)
• Depreciation: 224 (↑ 13 %)

---

Operational & Business Highlights

1. Contract Development & Manufacturing Organization (CDMO)

• Broad‑based growth across Indian and overseas sites, driven by healthy order inflows.
• Expanded commercial team improves market coverage and customer engagement.
• New commercial‑scale payload‑linker suite inaugurated at Riverview (US); Lexington (US) sterile injectable capacity expansion on track.
• Strategic partnership with Ajinomoto Bio‑Pharma Services for next‑gen conjugation technology.
• Maintained Zero OAI (Outstanding Action Item) status; Sellersville (US) received an FDA Establishment Inspection Report (EIR).

2. Complex Hospital Generics (CHG)

• Retained 48 % value share in the US sevoflurane market; gaining traction in select ex‑US inhalation‑anesthesia markets (IQVIA).
• Integration of Kenalog® progressing; supplies expected from Q2 FY27.
• Continued leadership in US intrathecal baclofen market (IQVIA).
• Ongoing collaborations to improve injectable pain‑management product availability.
• Investments in 505(b)(2) products, complex generics, and in‑licensing/co‑development initiatives.

3. Piramal Consumer Healthcare (PCH)

• Power Brands grew 23 % YoY, now contributing 53 % of Consumer Healthcare sales.
• E‑commerce grew 40 % YoY, accounting for 28 % of sales.
• Launched i‑choose, a unified master brand for women’s intimate‑care portfolio.
• Brand‑investment of ~12 % of sales across digital and traditional media.
• Premiumisation, disciplined pricing, and cost‑optimization helped mitigate raw‑material inflation and supported EBITDA performance.

4. Quality & Compliance

• Sellersville (US) facility successfully concluded FDA inspection, receiving an EIR.
• The company continues to maintain a Zero OAI track record to date.

---

Management Commentary

“We have started FY27 on a strong note, with all three businesses delivering mid‑to‑high‑teens revenue growth alongside meaningful EBITDA margin expansion… We look forward to delivering sustained revenue growth and EBITDA expansion through FY27, while staying agile amid a dynamic external environment.”
— Nandini Piramal, Chairperson

---

Investor & Analyst Call

• Date: 30 July 2026
• Time: 09:30 AM – 10:15 AM IST (multiple global dial‑in numbers provided)
• Purpose: Discuss Q1 FY27 results.

---

Forward‑Looking Statements & Risk Disclaimer

The presentation contains forward‑looking statements that involve known and unknown risks, including execution of strategy, regulatory approvals, macro‑economic conditions, and market dynamics. Actual results may differ materially from those projected.

---

Contact Information

• Investor Relations & Enterprise Risk Management: Gagan Borana – gagan.borana@piramal.com
• Investor Relations: Madhusudan Dalmia – madhusudan.dalmia@piramal.com
• Media Queries: Madiha Vahid – madiha.vahid@piramal.com

---

All figures are unaudited and presented in Indian Rupees (₹) crore unless otherwise noted.